New York, NY – Pfizer Inc. (NYSE: PFE) today announced its financial guidance for the full year 2026 and updated its revenue outlook for 2025. The company reaffirmed its commitment to innovation and long-term growth while continuing to invest in its R&D pipeline and recently acquired assets.
For full-year 2026, Pfizer expects total revenues to range from $59.5 billion to $62.5 billion, reflecting anticipated lower sales from COVID-19 products and certain therapies facing loss of exclusivity. Adjusted research and development (R&D) expenses are projected between $10.5 billion and $11.5 billion, while adjusted selling, informational, and administrative (SI&A) expenses are expected to be between $12.5 billion and $13.5 billion. Pfizer anticipates adjusted diluted earnings per share (EPS) for 2026 in the range of $2.80 to $3.00.
For full-year 2025, Pfizer revised its revenue guidance to approximately $62.0 billion while maintaining its prior guidance for adjusted EPS. The adjustments reflect anticipated product demand shifts and market dynamics, including the gradual decline in COVID-19 product revenues.
“2025 was a year of strong execution and strategic advancement for Pfizer,” said the company’s CEO. “Looking ahead to 2026, we remain focused on delivering innovative medicines and vaccines that improve patient lives while supporting long-term shareholder value.”
Pfizer will host a live conference call and webcast today at 8:00 AM EST to discuss its guidance and outlook. The presentation and replay will be available at www.pfizer.com/investors.
About Pfizer
Pfizer is a global biopharmaceutical company dedicated to discovering, developing, and delivering medicines and vaccines that transform patient care. Its work spans oncology, immunology, vaccines, rare diseases, and more, reaching millions of patients worldwide.
By
